EXEL · Exelixis Inc
Price
Snapshot
50 fields · last close| Market Cap | $14.46B |
| P/E | 16.80 |
| Float | 246.6M |
| Beta | 0.48 |
| Volatility | 12.0% |
| Exchange | NASDAQ |
| Sector | Biotechnology |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 76 |
| Price | 57.45 |
| Change | −1.56% |
| Prev Close | 58.36 |
| Open | 58.28 |
| Day Low | 57.90 |
| Day High | 59.15 |
| Avg Vol | 2 |
| Avg $ Vol | $135.5M |
| 52W High | 59.72 |
| 52W Low | 33.76 |
| 52W Pos | 91.3% |
| From High | −3.80% |
| From Low | +70.17% |
| Max DD 1Y | −16.47% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +1.18% |
| SMA 50 | +3.72% |
| SMA 200 | +18.94% |
| RSI (14) | 59.0 |
| Vol 30D | 31.5% |
| Vol 90D | 34.0% |
| 1Y Range | 34–60 |
| Daily bars | 516 |
| Perf Week | +3.99% |
| Perf Month | +7.30% |
| Perf Quarter | +12.43% |
| Perf Half Y | +41.44% |
| Perf Year | +44.31% |
| Perf YTD | +31.83% |
| Prev Day | −1.56% |
| Clavix | B+ |
| Debt / Eq | 0.00 |
| Curr Ratio | 3.56 |
| Int Cover | 5.1× |
| FCF Margin | 50.3% |
| Rev Growth | +10.6% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 11 / 35 |
Clavix risk grade
regraded every trading dayEXEL grades B+, 76 of 100. Steadiest on Macro Resilience (67), most exposed on Price Stability (61, mixed). 4 of the 4 weighted dimensions sit above the Biotechnology median. Ranks 11 of 35 in Biotechnology by Clavix score.
How rough the ride is
| EXEL | Biotechnology median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.48 | 0.51 |
| Volatilityannualized | 12.0% | 13.4% |
| Max drawdown, past yearworst peak-to-trough fall | −16.5% | — |
| Typical daily movemedian absolute daily change | 1.21% | — |
| Days beyond ±3%of the last 252 sessions | 3614% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| EXEL | Biotechnology median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.48 | 0.51 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low56% of 36 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Biotechnology names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| EXEL | |
|---|---|
| 1 week | +4.0% |
| 1 month | +7.3% |
| Year to date | +31.8% |
| 1 year | +44.3% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| EXEL | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 25 Aug |
| Average score0 most bearish, 100 most bullish | 56 |
| Bullish · bearisharticles above 60 · below 40 | 18 · 9 |
| Directionarticles whose tone is improving vs worsening | 18 ↑ 9 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 36 Biotechnology names Clavix covers; the tick is the sector median.
Growth
| EXEL | |
|---|---|
| Revenue growthyear over year | +10.6% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Biotechnology median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openExelixis CEO Michael Morrissey said the company plans to grow its cancer drug business through internal development, selective deals and partnerships, while preparing to launch its drug zanzalintinib for colorectal cancer that has spread to other parts of the body. The company's existing drug cabozantinib has crossed $3 billion (in sales).
Exelixis said the FDA extended its review of the drug zanzalintinib by three months after the agency asked for updated safety and effectiveness information, pushing the target decision date to March 3, 2027. The company submitted the additional data, which the FDA classified as a major amendment (a significant change to the application that resets the review clock).
Exelixis executives said at a Wells biotech event that the company plans to keep expanding its CABOMETYX cancer drug franchise and is preparing for a potential launch of zanzalintinib (called 'zanza') in colorectal cancer later this year. The headline also notes that CABOMETYX growth is facing hurdles related to its ramp in neuroendocrine tumors (NET). The article body was cut off, so further details were not available.
Exelixis executives laid out a growth strategy focused on expanding its drug CABOMETYX into new cancer types and advancing its experimental drug zanzalintinib through several late-stage clinical trials.
Exelixis executives laid out a growth strategy centered on expanding CABOMETYX into renal cell carcinoma (kidney cancer) and neuroendocrine tumors (rare tumors of hormone-producing cells), while moving zanzalintinib, an experimental cancer treatment, through several late-stage clinical trials.
Nearest peers by size
Biotechnology| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ASND | Ascendis Pharma A/S | B+ | $14.77B | 17.33 | 0.40 | Compare |
| NBIX | Neurocrine Biosciences Inc | B+ | $14.86B | 21.07 | 0.37 | Compare |
| BBIO | BridgeBio Pharma Inc | B | $13.02B | — | 0.98 | Compare |
| HALO | Halozyme Therapeutics Inc | B | $12.76B | 30.86 | 0.96 | Compare |
| MDGL | Madrigal Pharmaceuticals Inc | B | $12.28B | — | -1.09 | Compare |
| TWST | Twist Bioscience Corp | D+ | $10.99B | — | 2.23 | Compare |
| KRYS | Krystal Biotech Inc | B | $9.97B | 41.27 | 0.56 | Compare |
| UTHR | United Therapeutics Corp | A- | $21.22B | 16.18 | 0.51 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.